Key result
Estimated urinary sodium excretion >7g/day was associated with an increased risk of death, myocardial infarction, stroke, or heart failure compared to 5-6g/day (OR 1.73; 95% CI 1.24-2.40; P<0.001).
Why the study?
Does urinary sodium excretion level affect the risk of cardiovascular events and mortality in South American adults?
Cohort (n=17,033)
Yes
Does urinary sodium excretion level affect the risk of cardiovascular events and mortality in South American adults?
Odds Ratio: 1.73 (95% CI 1.24–2.4)
p-value: p=< 0.001
Both high (>7g/day) and low (<3g/day) estimated urinary sodium excretion are associated with increased cardiovascular risk compared to moderate levels (5-6g/day), supporting a J-shaped relationship.
High sodium excretion was associated with higher CV risk in South Americans; supports J-shaped curve but leaves causal effects and practice change open.
BACKGROUND: Information on actual sodium intake and its relationships with blood pressure (BP) and clinical events in South America is limited. The aim of this cohort study was to assess the relationship of sodium intake with BP, cardiovascular (CV) events, and mortality in South America. METHODS: We studied 17,033 individuals, aged 35-70 years, from 4 South American countries (Argentina, Brazil, Chile, and Colombia). Measures of sodium excretion, estimated from morning fasting urine, were used as a surrogate for daily sodium intake. We measured BP and monitored the composite outcome of death and major CV events. RESULTS: Overall mean sodium excretion was 4.70±1.43g/day. A positive, nonuniform association between sodium and BP was detected, with a significant steeper slope for the relationship at higher sodium excretion levels (P < 0.001 for interaction). With a median follow-up of 4.7 years, the primary composite outcome (all-cause death, myocardial infarction, stroke, or heart failure) occurred in 568 participants (3.4%). Compared with sodium excretion of 5-6g/day (reference group), participants who excreted >7g/day had increased risks of the primary outcome (odds ratio (OR) 1.73; 95% confidence interval (CI) 1.24 to 2.40; P < 0.001), as well as death from any cause (OR 1.87; 95% CI 1.23 to 2.83; P = 0.003) and major CV disease (OR 1.77; 95% CI 1.12 to 2.81; P = 0.014). Sodium excretion of <3g/day was associated with a statistically nonsignificant increased risk of the primary outcome (OR 1.20; 95% CI 0.86 to 1.65; P = 0.26) and death from any cause (OR 1.25; 95% CI 0.81 to 1.93; P = 0.29), and a significant increased risk of major CV disease (OR 1.50; 95% CI 1.01 to 2.24; P = 0.048), as compared to the reference group. CONCLUSIONS: Our results support a positive, nonuniform association between estimated urinary sodium excretion and BP, and a possible J-shaped pattern of association between sodium excretion over the entire range and clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Lamelas et al. (2015) reported a cohort. Urinary sodium excretion >7g/day vs. Urinary sodium excretion of 5-6g/day was evaluated on all-cause death, myocardial infarction, stroke, or heart failure (OR 1.73, 95% CI 1.24 to 2.40, p=< 0.001). Estimated urinary sodium excretion >7g/day was associated with an increased risk of death, myocardial infarction, stroke, or heart failure compared to 5-6g/day (OR 1.73; 95% CI 1.24-2.40; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: